Imunon (NASDAQ:IMNN) Receives Buy Rating from D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Imunon (NASDAQ:IMNN) in a research note issued to investors on Thursday,Benzinga reports. D. Boral Capital currently has a $29.00 price target on the stock.

Separately, HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of Imunon in a report on Thursday, December 19th.

Imunon Price Performance

Shares of NASDAQ IMNN opened at $0.81 on Thursday. Imunon has a 1-year low of $0.64 and a 1-year high of $3.65. The business’s 50 day moving average is $0.89 and its two-hundred day moving average is $0.95. The stock has a market capitalization of $11.75 million, a P/E ratio of -0.43 and a beta of 2.03.

Hedge Funds Weigh In On Imunon

An institutional investor recently raised its position in Imunon stock. Geode Capital Management LLC grew its holdings in shares of Imunon, Inc. (NASDAQ:IMNN) by 10.8% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 139,505 shares of the company’s stock after buying an additional 13,570 shares during the quarter. Geode Capital Management LLC owned 0.96% of Imunon worth $133,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 4.47% of the company’s stock.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.